(NASDAQ:VRSK), JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, will report its financial results for the fourth quarter and fiscal year ended December 31, 2025, on Wednesday, February 18, 2026, before the market open. The press release, with […]
(NASDAQ:NAOV),(NASDAQ:FEED), TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In
(NASDAQ:LIVE), LAS VEGAS and FAIRFIELD, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures”), a diversified holding company, today announced that its Flooring Liquidators, Inc. (“Flooring Liquidators”) subsidiary has deployed artificial intelligence as a core operational intelligence system, transforming raw transactional data into predictive business insights that are reshaping inventory
(NasdaqGM:SLXN), Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.   The 7th RNAi-Based Therapeutics Summit is the industry's premier forum
NEW YORK and LONDON, Jan. 21, 2026 (GLOBE NEWSWIRE) — Filament Syfter, a pioneering, category-defining dealmaking data platform that empowers private market dealmakers to unify data and unleash AI, announced today it is rebranding to Deal Engine. Since 2016, the company has partnered with private equity and investment banking firms to overcome a perennial private
(NASDAQ:ENTX), Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE)
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts GlobeNewswire January 21, 2026 BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) — NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company
GOSUBETTING.com Announces Launch of Bitcoin-first Sports Betting Research Platform GlobeNewswire January 21, 2026 London, UK, Jan. 21, 2026 (GLOBE NEWSWIRE) — GOSUBETTING is excited to announce the launch of its bitcoin-first sports betting research platform, which reviews and compares crypto sportsbooks through real-money testing, payout tracking, and transparent methodology, without hype or recycled affiliate content,
Ekso Bionics Prices $5.852 million Private Placement GlobeNewswire January 21, 2026 SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and
SurgePays Announces Pricing of $2.5 Million Public Offering GlobeNewswire January 21, 2026 BARTLETT, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG), a wireless and fintech point of sale company connecting subprime and underserved consumers to essential mobile and financial services, today announced the pricing of its previously announced underwritten public offering of